Company Overview of Evonik Industries AG
Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemical quaternary derivatives, polyurethane additives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, and animal nutrition and healthcare products. The Resource Efficiency segment provides high-performance materials and specialty additives, such as hydrogen pe...
Rellinghauser Strasse 1-11
Key Executives for Evonik Industries AG
CEO & Chairman of the Executive Board
Total Annual Compensation: €1.3M
CFO & Member of Executive Board
Total Annual Compensation: €1.4M
Chief Human Resources Officer & Member of Executive Board
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2016.
Evonik Industries AG Key Developments
Evonik Industries AG Proposes Dividend
Mar 6 18
Evonik Industries AG at its Annual Shareholders' Meeting on May 23, 2017, the Executive Board and Supervisory Board will be proposing a dividend of EUR 1.15 per share.
Evonik Industries Ag Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017; Provides Earnings Guidance for 2018
Mar 6 18
Evonik Industries AG announced earnings results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported sales of €3,567 million against €3,205 million a year ago. Adjusted EBITDA was €474 million against €437 million a year ago. Adjusted EBIT was €233 million against €258 million a year ago. Income before income taxes, continuing operations was €120 million against €190 million a year ago. Income after taxes, continuing operations was €109 million against €124 million a year ago. Income after taxes was €105 million against €219 million a year ago. Net income was €103 million against €216 million a year ago. Adjusted net income was €186 million against €182 million a year ago.
For the full year, the company reported sales of €14,419 million against €12,732 million a year ago. Adjusted EBITDA was €2,360 million against €2,165 million a year ago. Adjusted EBIT was €1,490 million against €1,448 million a year ago. Income before income taxes, continuing operations was €1,027 million against €1,124 million a year ago. Income after taxes, continuing operations was €734 million against €762 million a year ago. Income after taxes was €734 million against €858 million a year ago. Net income was €717 million against €844 million a year ago. Adjusted net income was €1,010 million against €930 million a year ago. The increase in sales in 2017 was driven by organic growth and by consolidation of the specialty additives business acquired from Air Products and the Huber silica business.
The company aims to grow sales and operating earnings in 2018 and expects adjusted EBITDA to be between €2.4 billion and €2.6 billion. Evonik had a good start to the year. Capital expenditures is expected to be €1 billion. Keeping total capital expenditures below prior-year level, even though investment in world-scale plant for feed additives in Singapore will double - compared with 2017 - to around 300 million. Alongside expected earnings growth and increased cost-awareness, strict capital discipline will result in slight increase in free cash flow.
AkzoNobel Specialty Chemicals and Evonik Industries Start Up Joint Venture Plant for Chlorine and Potassium Hydroxide
Feb 15 18
AkzoNobel Specialty Chemicals and Evonik Industries have successfully started production at their new joint venture to produce chlorine and potassium hydroxide at the companies Ibbenbren site in Germany. The facility uses membrane electrolysis technology to produce up to 120,000 metric tons of potassium hydroxide and 75,000 metric tons of chlorine per year, as well as hydrogen. The plant will strengthen the respective leading positions of both companies. AkzoNobel Specialty Chemicals will receive chlorine and hydrogen, while Evonik will market the potassium hydroxide from the facility and convert part of the output at its Llsdorf site into other products, including potassium carbonate, potassium bicarbonate and potassium formate. AkzoNobel and Evonik start up joint venture plant for chlorine and potassium hydroxide. The sites new production process will improve the ecological footprint of every ton of chlorine produced in Ibbenbren by 25 to 30%. This will result in less energy use, lower costs and fewer CO2 emissions.
Similar Private Companies By Industry
Recent Private Companies Transactions